NW 2 146
Alternative Names: NW-2-146Latest Information Update: 07 Jul 2022
Price :
$50 *
At a glance
- Originator Newave Pharmaceuticals
- Developer Guangzhou Lupeng Pharmaceutical; Newave Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 23 Jun 2022 Early research in Cancer in USA (unspecified route) (Guangzhou Lupeng Pharmaceutical pipeline; 20 June 2022)
- 22 Jun 2022 Early research in Cancer in China (unspecified route) (Guangzhou Lupeng Pharmaceutical pipeline; 20 June 2022)